Eli Lilly's $7 Billion Bet Targets Cancer Treatment at the Source [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Kelonia Therapeutics for up to $7 billion, with $3.25 billion payable upfront and the remainder tied to clinical, regulatory, and commercial milestones. The deal is expected to close in the second half of 2026, subject to regulatory approvals. Kelonia's lead program, KLN-1010, is a Phase 1 investigational therapy for relapsed and refractory multiple myeloma. The approach uses an in vivo gene delivery system to generate CAR-T cells directly inside the patient, removing the manufacturing complexity of existing treatments. Jacob Van Naarden, executive vice president and president of Lilly Oncology, called the early clinical data highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia's platform. The deal drops Lilly into a market with established players. Johnson & Johnson's ( NYSE:JNJ ) CAR-T treatment for multiple myeloma, Carvykti, generated $1.89 billion in sales last year, while Gilead ( NASDAQ:GILD ) recently p
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- A portfolio needs a decent mix between what's hot and what's not, says Jim Cramer [CNBC]CNBC
- Jim Cramer explains why he is wary of chasing ‘parabolic' stocks [CNBC]CNBC
- Global Foot and Ankle Devices Market to Observe Stunning Growth at a CAGR of ~8% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Put $5,000 In These Dividend Giants and Earn Passive Income Every Quarter [Yahoo! Finance]Yahoo! Finance
- Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion [MSNBC.com]MSNBC.com
JNJ
Earnings
- 4/14/26 - Beat
JNJ
Sec Filings
- 4/14/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website